mk 0663 has been researched along with thromboxanes in 2 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (thromboxanes) | Trials (thromboxanes) | Recent Studies (post-2010) (thromboxanes) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 3,202 | 149 | 199 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciabattoni, G; Davì, G; Dragani, A; Ferrante, E; Habib, A; Lattanzio, S; Mattoscio, D; Mucci, L; Pascale, S; Patrono, C; Petrucci, G; Ranelletti, FO; Recchiuti, A; Rocca, B | 1 |
| Hjemdahl, P; Stiller, CO | 1 |
1 review(s) available for mk 0663 and thromboxanes
| Article | Year |
|---|---|
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes | 2022 |
1 trial(s) available for mk 0663 and thromboxanes
| Article | Year |
|---|---|
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.
Topics: Adult; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Etoricoxib; Female; Humans; Immunohistochemistry; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Sulfones; Thrombocythemia, Essential; Thromboxane A2; Thromboxane B2; Thromboxanes; Treatment Outcome | 2010 |